Acute lymphoblastic leukemia (ALL) poses a significant challenge due to its high relapse rate despite initial chemotherapy. Cell therapy plays an important and promising role in refractory ALL cases. The aim is to present a complex case of a 20-year-old male patient with relapsed ALL and to explore the different therapeutic options of cellular therapy - allogeneic hematopoietic stem cell transplantation, donor lymphocyte infusion, and chimeric antigen receptor T - detailing the collection, processing, and infusion, as well as the associated complications and management strategies. Data were collected from patient records. This case highlights the evolving landscape of immunotherapy in hematological malignancies and emphasizes the importance of optimizing cellular therapy approaches for improved patient outcomes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730476 | PMC |
http://dx.doi.org/10.7759/cureus.75730 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!